Targeted Gene Panel Testing Can Assist Patients With RCC, Germline Mutations
Read the full article here
Read the full article here
Example
Drs. Thomas Zilli and Pierre Blanchard join The Uromigos at APCCC 2024 to debate the use of radiation therapy in prostate cancer and oligometastatic disease.
Drs. Murray and Broenimann highlight and evaluation of urinary genomic profiling for detection and molecular staging of UTUC.
A study to determine the potential utility of ADCs targeting TROP-2 in both localized PSCC and distant metastases.
Dr. Li highlights the significance of adverse pathologic features at radical prostatectomy for AS-eligible patients.
Enzalutamide and lutetium-177–labeled prostate-specific membrane antigen-617 have both been proven to improve OS rates in patients with mCRPC.
Drs. Joyce and Psutka consider patient counseling for adjuvant RCC therapy, and biomarkers and imaging before treatment.
Brian and Tom speak with Drs. Piet Ost and Jason Efstathiou at ASCCC 2024 to discuss the data for and against the use of radiation…
Continuing his discussion at the AUA 2024 Annual Meeting, Dr. Narayan highlights the latest news on nadofaragene firadenovec.
Tom and Brian are joined by David Penson to discuss upcoming presentations to look forward to at AUA, including new muscle-invasive bladder cancer research.
The utility of cADT in patients with prostate cancer with clinical relapse at PSMA PET is unknown.